Шифр: AE1/2014/25/8 Журнал 2014р. Vol. 25 N 8 Leighl, N. B. Early-stage lung cancer-what do the experts recommend? / N. B. Leighl, G. Curigliano. - P.1452-1453 Denkert, C. The immunogenicity of breast cancer-molecular subtypes matter / C. Denkert. - P.1453-1455 Curigliano, G. Immunoscoring breast cancer: TILs remember what they target / G. Curigliano, E. A. Perez. - P.1455-1456 Quinn, D. I. Carboplatin's fourth decade: still searching for its sweet spot / D. I. Quinn. - P.1457-1458 Casali, P. G. Risks of the new EU Data protection regulation: an ESMO position paper endorsed by the European oncology community / P. G. Casali. - P.1458-1460 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. - P.1462-1474 Інші автори: Vansteenkiste J., Crinò L., Dooms C., Douillard J. Y., Faivre-Finn C., Lim E., Rocco G., Senan S., Van Schil P., Veronesi G., Stahel R., Peters S., Felip E. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. - P.1475-1484 Інші автори: Besse B., Adjei A., Baas P., Meldgaard P., Nicolson M., Paz-Ares L., Reck M., Smit E. F., Syrigos K., Stahel R., Felip E., Peters S. Quality assurance in the treatment of colorectal cancer: the EURECCA initiative. - P.1485-1492 Інші автори: Breugom A. J., Boelens P. G., van den Broek C. B. M., Cervantes A., Van Cutsem E., Schmoll H. J., Valentini V., van de Velde C. J. H. Early recognition of malnutrition and cachexia in the cancer patient: a position paper of a European School of Oncology Task Force. - P.1492-1499 Інші автори: Aapro M., Arends J., Bozzetti F., Fearon K., Grunberg S. M., Herrstedt J., Hopkinson J., Jacquelin-Ravel N., Jatoi A., Kaasa S., Strasser F. ENCCA WP17-WP7 consensus paper on teenagers and young adults (TYA) with bone sarcomas. - P.1500-1505 Інші автори: Wilhelm M., Dirksen U., Bielack S. S., Whelan J. S., Lewis I. J., Jürgens H., Ferrari S., Sundby Hall K., Cleton-Jansen A. M., Stark D. Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research. - P.1506-1516 Інші автори: Grover P. K., Cummins A. G., Price T. J., Roberts-Thomson I. C., Hardingham J. E. Smoking and survival of colorectal cancer patients: systematic review and meta-analysis. - P.1517-1525 Інші автори: Walter V., Jansen L., Hoffmeister M., Brenner H. Alcohol and liver cancer: a systematic review and meta-analysis of prospective studies. - P.1526-1535 Інші автори: Turati F., Galeone C., Rota M., Pelucchi C., Negri E., Bagnardi V., Corrao G., Boffetta P., La Vecchia C. Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients. - P.1536-1543 Інші автори: Ali H. R., Provenzano E., Dawson S.-J., Blows F. M., Liu B., Shah M., Earl H. M., Poole C. J., Hiller L., Dunn J. A., Bowden S. J., Twelves C., Bartlett J. M. S., Mahmoud S. M. A., Rakha E., Ellis I. O., Liu S., Gao D., Nielsen T. O., Pharoah P. D. P., Caldas C. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. - P.1544-1550 Інші автори: Loi S., Michiels S., Salgado R., Sirtaine N., Jose V., Fumagalli D., Kellokumpu-Lehtinen P.-L., Bono P., Kataja V., Desmedt C., Piccart M. J., Loibl S., Denkert C., Smyth M. J., Joensuu H., Sotiriou C. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. - P.1551-1557 Інші автори: Nitz U., Gluz O., Huober J., Kreipe H. H., Kates R. E., Hartmann A., Erber R., Scholz M., Lisboa B., Mohrmann S., Möbus V., Augustin D., Hoffmann G., Weiss E., Böhmer S., Kreienberg R., Du Bois A., Sattler D., Thomssen C., Kiechle M., Jänicke F., Wallwiener D., Harbeck N., Kuhn W. Controversial issues in early-stage breast cancer: a global collaborative survey, supported by the European Society for Medical Oncology (ESMO). - P.1558-1561 Інші автори: Zardavas D., Ades F., Spasojevic I. B., Pugliano L., Capelan M., Paesmans M., de Azambuja E., Piccart M. Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial. - P.1563-1570 Інші автори: Kramar A., Bachelot T., Madrange N., Pierga J.-Y., Kerbrat P., Espié M., Fumoleau P., Pauporté I., Khayat D., Romieu G., Pivot X. Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact. - P.1571-1577 Інші автори: Nabholtz J. M., Abrial C., Mouret-Reynier M. A., Dauplat M. M., Weber B., Gligorov J., Forest A. M., Tredan O., Vanlemmens L., Petit T., Guiu S., Van Praagh I., Jouannaud C., Dubray-Longeras P., Tubiana-Mathieu N., Benmammar K. E., Kullab S., Bahadoor M. R. K., Radosevic-Robin N., Kwiatkowski F., Desrichard A., Cayre A., Uhrhammer N., Chalabi N., Chollet P., Penault-Llorca F. Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer. - P.1578-1584 Інші автори: Mok T. S., Geater S. L., Iannotti N., Thongprasert S., Spira A., Smith D., Lee V., Lim W. T., Reyderman L., Wang B., Gopalakrishna P., Garzon F., Xu L., Reynolds C. SNPs in the transforming growth factor-β pathway as predictors of outcome in advanced lung adenocarcinoma with EGFR mutations treated with gefitinib. - P.1584-1590 Інші автори: Zhang L., Li Q. X., Wu H. L., Lu X., Yang M., Yu S. Y., Yuan X. L. Relevant risk of carboplatin underdosing in cancer patients with normal renal function using estimated GFR: lessons from a stage I seminoma cohort. - P.1591-1597 Інші автори: Cathomas R., Klingbiel D., Geldart T. R., Mead G. M., Ellis S., Wheater M., Simmonds P., Nagaraj N., von R. Moos, Fehr M. Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study. - P.1597-1603 Інші автори: Buzzoni R., Pusceddu S., Bajetta E., De Braud F., Platania M., Iannacone C., Cantore M., Mambrini A., Bertolini A., Alabiso O., Ciarlo A., Turco C., Mazzaferro V. A phase I study of cabozantinib (XL184) in patients with renal cell cancer. - P.1604-1608 Інші автори: Choueiri T. K., Pal S. K., McDermott D. F., Morrissey S., Ferguson K. C., Holland J., Kaelin W. G., Dutcher J. P. Plasma methionine, choline, betaine, and dimethylglycine in relation to colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). - P.1609-1615 Інші автори: Nitter M., Norgård B., de Vogel S., Eussen S. J. P. M., Meyer K., Ulvik A., Ueland P. M., Nygård O., Vollset S. E., Bjørge T., Tjønneland A., Hansen L., Boutron-Ruault M., Racine A., Cottet V., Kaaks R., Kühn T., Trichopoulou A., Bamia C., Naska A., Grioni S., Palli D., Panico S., Tumino R., Vineis P., Bueno-de-Mesquita H. B., van Kranen H., Peeters P. H., Weiderpass E., Dorronsoro M., Jakszyn P., Sánchez M., Argüelles M., Huerta J. M., Barricarte A., Johansson M., Ljuslinder I., Khaw K., Wareham N., Freisling H., Duarte-Salles T., Stepien M., Gunter M. J., Riboli E. Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial. - P.1616-1622 Інші автори: Glynne-Jones R., Kadalayil L., Meadows H. M., Cunningham D., Samuel L., Geh J. I., Lowdell C., James R., Beare S., Begum R., Ledermann J. A., Sebag-Montefiore D. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. - P.1622-1628 Інші автори: Mounier N., Brice P. , Bologna S., Briere J., Gaillard I., M. Heczko, J. Gabarre, Casasnovas O., Jaubert J., Colin P., Delmer A., Devidas A., Bachy E., Nicolas-Virelizier E., Aoudjhane A., Humbrecht C., Andre M., Carde P. Comprehensive gene expression meta-analysis of head and neck squamous cell carcinoma microarray data defines a robust survival predictor. - P.1628-1635 Інші автори: De Cecco L., Bossi P., Locati L., Canevari S., Licitra L. Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a classification model—a study based on data from an international multicentre project (EPCRC-CSA). - P.1635-1642 Інші автори: Blum D., Stene G. B., Solheim T. S., Fayers P., Hjermstad M. J., Baracos V. E., Fearon K., Strasser F., Kaasa S.,on behalf of Euro-Impact Immigrants' perceptions of the quality of their cancer care: an Australian comparative study, identifying potentially modifiable factors. - P.1643-1649 Інші автори: Goldstein D., Bell M. L., Butow P., Sze M., Vaccaro L., Dong S., Liauw W., Hui R., Tattersall M., Ng W., Asghari R., Steer C., Vardy J., Parente P., Harris M., Karanth N. V., King M., Girgis A., Eisenbruch M., Jefford M. European cancer mortality predictions for the year 2014. - P.1650-1656 Інші автори: Malvezzi M., Bertuccio P., Levi F., La Vecchia C., Negri E. Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors. - P.1656-1663 Інші автори: Balmaña J., Tung N. M., Isakoff S. J., Graña B., Ryan P. D., Saura C., Lowe E. S., Frewer P., Winer E., Baselga J., Garber J. E. Malik, L. The dilemmas of breast cancer treatment and increased fracture risk / L. Malik. - P.1664 Bouvard, B. The dilemmas of breast cancer treatment and increased fracture risk by Malik / B. Bouvard, E. Legrand. - P.1664-1665 Laurent, M. R. Fracture incidence after 3 years of aromatase inhibitor therapy / M. R. Laurent, P. Neven, D. Vanderschueren. - P.1665-1666 Bouvard, B. Reply to the letter to the editor ‘Fracture incidence after 3 years of aromatase inhibitor therapy’ by Laurent et al. / B. Bouvard, E. Legrand. - P.1666-1667 Controversies and role of HPV16 in recurrent/metastatic squamous cell cancers of the head and neck. - P.1667-1668 Інші автори: Misiukiewicz K., Bonomi M., Demicco E., Posner M. Pre-cachexia: a non-existing phenomenon in cancer?. - P.1668-1669 Інші автори: Blauwhoff-Buskermolen S., de van der Schueren M. A. E., Verheul H. M. W., Langius J. A. E. Emile, G. Should we use the angiotensin-converting enzyme inhibitors for the treatment of anti-VEGF-induced hypertension? / G. Emile, E. Pujade-Lauraine, J. Alexandre. - P.1669-1670 RE: Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. - P.1670-1671 Інші автори: Diwakar D., Choi T., Tawbi T. H., Kirkwood J. M. Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer. - P.1672 Є примірники у відділах: всього 2 : ЧЗ (2) Вільні: ЧЗ (2) |